Multi-omics study reveals psychiatric comorbidities in bladder pain syndrome patients while demonstrating advantages in hematological malignancies and repeat expansion analysis.
New research demonstrates the ultra-sensitive SNV detection capabilities of ppmSeq technology, with error rates reaching as low as 8 x 10-8 for minimal residual disease applications.
The expanded testing capabilities leverage long-read sequencing technology to detect disorders such as Fragile X syndrome, adult neurological conditions, certain ataxias, and more.
VENTANA HER2 (4B5) test is now CE-IVDR approved to identify HER2-ultralow breast cancer and HER2-positive biliary tract cancer patients.
Read More
The clinician-ordered test integrates polygenic risk scores validated in over 236,000 participants from the NIH’s All of Us Research Program.
Read More
Study shows Foresight CLARITY demonstrated 68% pre-operative and 38% post-operative MRD detection rates in stage I lung cancer patients.
Read More
New offering combines genetic testing with clinical decision support tools to help optimize medication selection and dosing across multiple specialties.
Read More
The funding will support commercialization of the company’s extracellular vesicle-based liquid biopsy tests, starting with ovarian cancer screening.
Read More
The NGS-based test joins CE-IVD and NMPA approvals for global market access.
Read More
The DNA-based stool screening test is now authorized for marketing through the MHRA, expanding access to non-invasive CRC detection.
Read More
The urine-based NGS assay received Breakthrough Device Designation in 2022 and targets genomic alterations in cancer-associated genes.
Read More
The ARCHER study will evaluate shortened radiation therapy while using ctDNA testing to monitor treatment response and disease recurrence.
Read More
Johns Hopkins-led study identifies protein signature with 98% accuracy in distinguishing ALS patients from healthy individuals and those with other neurological diseases.
Read More
Multi-biomarker platform combining proteins, lipids, and machine learning outperforms traditional single-marker tests in 950-patient study.
Read More
The assay detected 51% more pathogenic variants and 109% more copy number variants compared to six commercial liquid biopsy assays in prospective validation study.
Read More
The kit aims to improve the detection of challenging transcripts, including rare isoforms and long noncoding RNAs.
Read More
The company’s be.well platform can detect seasonal influenza A and B as well as avian influenza A(H5) in humans within 45 minutes at the point of care.
Read More
The circulating tumor DNA test is designed to identify MRD-positive patients with stage II colorectal cancer who may benefit from adjuvant therapy.
Read More